{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:56:02Z","timestamp":1782528962460,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ensuring the safety of analgesics during lactation is crucial for women of childbearing potential. Available data regarding the transfer of nalbuphine for postoperative acute pain via breast milk are limited to the postmarketing experience. This lactation study aimed to assess nalbuphine and dinalbuphine sebacate concentrations in breast milk from lactating women with postoperative pain treated with dinalbuphine sebacate extended\u2010release injection (150 mg dinalbuphine sebacate\/2 mL Naldebain). Breast milk was collected throughout the 5\u2010day posthospitalization interval from 20 mothers injected with one dose of extended\u2010release dinalbuphine sebacate intramuscularly. Maternal safety was assessed during the study period. Nalbuphine was detectable in 71% of milk samples collected from all mothers, whereas dinalbuphine sebacate was undetectable or below the quantitation limit (0.1 ng\/mL). The mean nalbuphine concentration in milk was approximately 10.55 ng\/mL, with the peak concentration reaching up to 12.7 ng\/mL. The mean relative infant dose was 0.39% (coefficient of variation, 65%). The mean pain intensity at rest was reduced to mild pain from Day 2 morning to discharge. Overall, the maternal safety profile was tolerable. The breast milk of women who receive one dose of dinalbuphine sebacate injection postpartum contains low nalbuphine concentration. In addition, dinalbuphine sebacate injection potentially reduces maternal pain intensity during the first postpartum week and offers low toxicity risk among breastfed infants.<\/jats:p>","DOI":"10.1002\/jcph.2416","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T08:10:39Z","timestamp":1709280639000},"page":"755-761","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breast Milk Excretion of Dinalbuphine Sebacate Injection Administered After Cesarean Section"],"prefix":"10.1002","volume":"64","author":[{"given":"Sung\u2010Ling","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Tri\u2010Service General Hospital  Taipei Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai\u2010Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Lumosa Therapeutics  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Kai","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Lumosa Therapeutics  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi\u2010Kang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Tri\u2010Service General Hospital National Defense Medical Center  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-005671"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14538"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814040-00003"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2118"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000417"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S263315"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00197-x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S314304"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00383-z"},{"issue":"10","key":"e_1_2_10_11_1","first-page":"1496","article-title":"Elimination of nalbuphine in human milk","volume":"38","author":"Wischnik A","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31815d0f01"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00326-1"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2088"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04077.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00389.x"},{"issue":"10","key":"e_1_2_10_18_1","first-page":"S151","article-title":"Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications","author":"Ito S","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb03300.x"},{"issue":"1","key":"e_1_2_10_20_1","first-page":"14","article-title":"Injection site reactions before and after intramuscular injection technique revision: a postmarketing analysis of naldebain from 2017 to 2022","volume":"61","author":"Man KM","year":"2023","journal-title":"Asian J Anesthesiol"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen213"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2014.01.001"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2670(00)00963-6"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2530"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T13:45:03Z","timestamp":1716817503000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/jcph.2416"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2416","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}